SureTrader Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Bioelectronics Corp. (BIEL)

BIEL RSS Feed
Add BIEL Price Alert      Hide Sticky   Hide Intro
Moderator: yankee55, stockdarockk, REDZONE, Det_Robert_Thorne, dcsteve, seven-up
Search This Board:
Last Post: 5/3/2016 2:13:01 PM - Followers: 546 - Board type: Free - Posts Today: 65















http://finance.yahoo.com/news/bioelectronics-applauds-fdas-reclassification-nonthermal-123000975.html




 

Looks like FDA CLASS II OTC approval 02/20/2014 

Docket No. FDA-2012-N-0378 
Filed 02/19/2014 at 8:45 am; Publication Date: 02/20/2014 

SUMMARY: The Food and Drug Administration (FDA) is proposing to reclassify the shortwave diathermy (SWD) for all other uses, a preamendments class III device, into class II (special controls), and to rename the device "nonthermal shortwave therapy (SWT)." FDA is proposing this reclassification on its own initiative based on new information. FDA is also proposing a technical correction in the regulation for the carrier frequency for SWD and nonthermal SWT devices. This proposed action would implement certain regulatory requirements. 

After considering available information, including the recommendations of the panel meeting on nonthermal SWT devices held on May 21, 2013, FDA has reevaluated the risks to health associated with the use of nonthermal SWT and made revisions from those previously identified in a proposed rule issued in the Federal Register on July 6, 2012 (77 FR 39953). 

VI. Summary of Reasons for Reclassification 
Based on the comments from the 2013 Panel meeting, the comments received in response to FDA's prior proposed rule (77 FR 39953, July 6, 2012), and FDA's assessment of new, valid scientific data related to the health benefits and risks associated with nonthermal SWT, FDA is proposing that these devices should be reclassified from class III to class II 
http://www.ofr.gov/(S(rsqvwlmlrgnufyk2vypn53y2))/OFRUpload/OFRData/2014-03594_PI.pdf


Its Important to understand 

FDA pretty much changed the guidelines based on the clinical data and CEO Presentation, which in return confirms the products... 

In other words its compared to a (drug approval) that takes years of research and clinical data to get to this point... 

This move by the FDA awakens the Pharmaceutical companies and investment firms .... guys over the next 2weeks the word will get out and since BIEL already has products and patents which was granted in April 2013,... I'm thinking by December this baby could be high .20-30 

In less than 90 days === 

- Prepare all adverstising marketing 
- Consider Opportunities in the investing communities 
- Get all products approved (the clinical data is already done) 
- They already have Boots in UK which is part of Walgreen so expand into Walgreen, followed by many other sources...
 

MUST SEE  http://www.bielcorp.com/biel/wp-content/uploads/2014/01/Bioelectroceuticals-Mechanism-of-Action-Clinical-Evidence-Version-16.pdf


The Company

http://www.sec.gov/Archives/edgar/data/1320869/000120445906000825/exh1014.htm
 

We are the makers of ActiPatch Therapy, RecoveryRx Devices, HealFast Therapy and the Allay family of inexpensive, disposable drug-free anti-inflammatory devices.

Our revolutionary line of pain treatment products are sold in more than 35 countries, with the simple goal of changing the way people heal.

Patents::::   
https://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Bioelectronics+Corp.%22
 

Electromagnetic therapy device and methods

www.google.com/patents/US8412328
Grant - ‎Filed May 21, 2003 -Issued Apr 2, 2013 - ‎Andrew J. Whelan - ‎Bioelectronics Corp.
Systems and techniques for applying an electromagnetic field to bodily tissue include a self-contained and portable electromagnetic field ...
Overview - ‎Related - ‎Discuss
 

Electromagnetic therapy device

www.google.com/patents/EP1606010B1?cl=en
Grant - ‎Filed Mar 3, 2004 - ‎Issued Feb 22, 2012 - ‎Andrew J. Whelan - ‎Bioelectronics Corp.
Systems and techniques for applying an electromagnetic field to bodily tissue include a self-contained and portable electromagnetic field ...
Overview - ‎Related - ‎Discuss
 

Back pain belt

 

www.google.com/patents/USD638949
Grant - ‎Filed May 11, 2010 - ‎Issued May 31, 2011 - ‎John R. Martinez - ‎BioElectronics Corp.
FIGS. 1-7 are views of a back pain belt with an electromagnetic pulse delivery device inside the a mesh pocket on the belt. FIG. 1 is a front ...
Overview - ‎Related - ‎Discuss
 

Product package

 

www.google.com/patents/USD643306
Grant - ‎Filed Sep 21, 2010 - ‎Issued Aug 16, 2011 - ‎John Robert Martinez - ‎BioElectronics Corp.
FIG. 1 is a front perspective view of the outer portion of a product package showing our new design, with the inner portion thereof removed for ...
Overview - ‎Related - ‎Discuss
 


Its important to point out ::: 

From Oct 2013 ::: The innovation award we won from OTC Bulletin in March has yielded more than a good-looking plaque. Our products caught the attention of several interested parties including three of Europe’s largest pharmaceutical companiesWe are actively exploring distribution and co-branding licensing proposals with all three. In each case these proposals offer significant potential advantages to the company. The most immediate would be product sales to companies with well-established, funded marketing and sales channels, and licensing agreements with royalty income. This strategy maintains our first-to-market advantage while giving us access to a good 
income stream and marketing power and access to capital (without further dilution).Another advantage would be the spill-over affect associated with this co-branding alliance on our other brands and obtaining additional distribution in other regions. http://www.bielcorp.com/investors/letter-from-the-president/ 

2014 Oxford Pharmascience Group (OXP) is sponsoring BIELhttp://www.oxfordpharmascience.com/content/investors/share_price.asp 

Park Lane Hotel, Piccadilly, London 
Thursday, 6th March 2014 

http://www.otc-bulletin.com/awards/pdfs/Nominations-Supplement-2014.pdf

-----------------------------------------------------------------------------------------------------------------------------

BioElectronics is changing the way people heal around the world.  Our vision is to provide our highly effective and safe technological solution so people can live their lives pain-free. We recently received the "2009 Wall Street Journal Technology Innovation Awards" with our unique anti-inflammatory technology that reduces pain and edema. This technology is the platform for everything that we do. Our current strategic vision is to develop a number of strong brands that build upon our technological platform. Currently, the main applications are aimed at the OTC markets for back pain, knee pain and menstrual pain. We hope to introduce our technology to new markets and additional countries in the near future.  We look forward to serving you!


As of August 14, 2012
Authorized  3,000,000,000
Issued & Outstanding  2,569,448,291
Restricted  187,036,056
Non-Restricted  2,382,411,335
Shareholders  195


Transfer Agent:
Holladay Stock Transfer
2939 N. 67th Place
Scottsdale, AZ 85251

1- 480-481-3940
 

E & E Communications New Contact Information
E-mail address remains:  pknopick@eandecommunications.com
New Texas phone number: 940.262.3584.
 

Retail Products 
What is ActiPatch®?
Recognized by the Wall Street Journal as one of the top medical innovations of 2009, ActiPatch® delivers its patented BioDynamic Therapy to not only relieve your pain, but to HEAL it so it doesn't come back.  Drugs and heat patches don't work to cure your pain - they simply mask it.  It always comes back.  Introducing a breakthrough in pain relief!


How does ActiPatch® work?

When cells are damaged, inflammation sets in resulting in pain, swelling, and reduced cellular energy.  ActiPatch® calms the inflammation and restores cells to their normal energy levels.  The result:  your pain and swelling diminish and your damaged cells actually begin to heal for sustained relief.  For more information visit the Technology section of our web site.

Is ActiPatch® Safe?

ActiPatch® is extremely safe and comfortable to wear. The low level current that is gently pulsed into damaged tissue is undetectable, even though the device is continuously working to help you heal. 



ActiPatch® in Canadian News    - Last week in Canada, the CHCH network in Ontario featured ActiPatch in a segment on their News Now program.  In the segment, Hudson Levy, ActiPatch Brand Manager discussed the benefits of the product and explained the technology driving BioDynamic Therapy™.  The Segment was well received and the footage was viewed by thousands of Canadians.  See the segment below:

 


 

  http://www.allaystore.com

 

 

 

What is Allay? 

Allay is a safe, drug-free solution to pain and discomfort associated with menstruation. Recognized by the Wall Street Journal as one of the top medical innovations of 2009, Allay draws on an innovative delivery system which emits low-level energy pulses which quickly relieve edema, inflammation, and pain, providing patient comfort and speeding up the onset of natural healing. Allay is recommended by physicians as a safe and effective treatment. In fact, clinical study results show that 77.1% of women using Allay reported complete elimination or significant reduction in their typical menstrual symptoms.

What's Inside?

Allay is a miniaturized medical device which delivers low-level energy pulses into your abdominal region to lessen contractions and alleviate the pain and discomfort resulting from menstruation. The unit consists of a control module containing the wafer-thin microchip and battery, which is connected to a flexible loop that bends to meet the contours of a woman's body. The control unit and loop are contained within a soft, hypoallergenic biodegradable sleeve ("Wrap") that is comfortably worn against the skin at the site of menstrual pain, cramping, and discomfort.

Inside the box, you will find:

  • 1 12cm Allay Loop Device Inside a Cloth Wrap
    1 Pouch (Allay device inside)
    9 Additional Cloth Wraps!
Allay is currently being sold in over 40 countries worldwide.

 
HealFast®  Therapy is a drug-free therapy for horses, cats and dogs that reduces swelling and pain while it speeds healing of muscle and tendon injuries, sores and incisions.   Animal muscle and skin tissues are composed of cell networks in which cell-cell communication relies extensively on cell-cell contact.   When there is an injury in soft tissue from whatever source - cut, sprain, arthritis - the swelling tissues disrupt cell-cell communication and delay healing.   HealFast therapy acts on the cells within a tissue boosting the energy in the cell membrane returning tissues to healthy function faster.
 

To receive investor updates via e-mail, please contact us at IR@bielcorp.com with your name and e-mail address. Updates are posted every other Thursday. Thank you for your support!

3,071 likes · 1,107 talking about this

 

Market Clearances

BioElectronics Corporation Worldwide Class IIa OTC Market Clearances

Country

Menstrual Pain

Musculoskeletal Pain

Postoperative Recovery/Chronic Wounds

All European Union Countries

x

x

x

Australia

x

x

x

Canada

x

x

x

China

   

Working on Clearance

Colombia

x

x

x

Croatia

x

x

x

India

 

Working on Clearance

 

Iran

x

x

x

Israel

x

x

x

Italy

x

x

x

Jordan

x

x

x

Korea

 

x

 

Kuwait

x

x

x

Mexico

Working on Clearance

Working on Clearance

Working on Clearance

Morocco

x

x

 

New Zealand

x

x

x

Nigeria

x

x

x

Peru

x

x

x

Spain

x

x

x

United States

Working on Clearance

Working on Clearance

Class III

Taiwan

Working on Clearance

Working on Clearance

Working on Clearance

Venezuela

Working on Clearance

Working on Clearance

Working on Clearance


                                                                                                                                                                                                        
Distributors

To order ActiPatch® online from Canada, please visit www.actipatch.ca

To order ActiPatch® online from Europe, please visit www.actipatchrelief.co.uk

 

Territory

Distributor

Products Distributed

Website

Albania Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Andorra Palex Medical SA ActiPatch, Allay & RecoveryRx www.palexmedical.com/en/
Australia Emergy Products ActiPatch, Allay & RecoveryRx www.emergyproducts.gr
Bosnia & Herzegovina Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Bulgaria Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Canada (ActiPatch online) BioElectronics Corporation ActiPatch www.actipatch.ca
Canada (ActiPatch online) Clearpoint Direct ActiPatch www.clearpointdirect.com
Canada (Allay online) BioElectronics Corporation Allay www.allaystore.com
China Shanghai Lixiu Medical Devices Co. RecoveryRx www.surgithes.com
Costa Rica Alfa Medica S.A. ActiPatch & Allay www.alfamedicacr.com
Croatia Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Cyprus Emergy Products ActiPatch, Allay & RecoveryRx www.myactipatch.gr, www.myallay.gr
Czech Republic easyMed s.r.o. ActiPatch & RecoveryRx www.easy-med.us
Denmark Maersk - Anderson ActiPatch & Allay www.c-m-a.dk
Ecuador Alboquin S.A. RecoveryRx & Allay www.maxbetsa.com
El Salvador Red-Medyci, S.A de C.V. ActiPatch, Allay & RecoveryRx www.redmedyci.com
Europe (online) Amazon UK ActiPatch & Allay www.actipatchrelief.co.uk
Greece Emergy Products ActiPatch, Allay & RecoveryRx www.myactipatch.gr, www.myallay.gr
Guatemala Red-Medyci, S.A de C.V. ActiPatch, Allay & RecoveryRx www.redmedyci.com
India Juno Pharmaceuticals ActiPatch www.actipatch.in
Iran Nik Day Arya Co., Ltd ActiPatch, Allay & RecoveryRx

-

Ireland O'neill healthcare RecoveryRx

-

Israel International Medical Trade & Consultants ActiPatch, Allay & RecoveryRx www.imtc.co.il
Jordan Achilles Medical ActiPatch www.achilles.com
Kosovo Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Macedonia Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Malaysia Qianjing Malaysia ActiPatch & Allay www.qjmedic.com
Malta Sidroc ActiPatch www.sidroc.com
Montenegro Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Morocco Noveq LLC. ActiPatch & Allay www.noveq.com
New Zealand Emergy Products ActiPatch, Allay & RecoveryRx www.emergyproducts.gr
Nigeria Alpha Pharmacy and Stores Ltd. ActiPatch & Allay www.alphapharmacyltd.com
Portugal Palex Medical SA ActiPatch, Allay & RecoveryRx www.palexmedical.com/en/
Saudi Arabia Sultanah Holding Group ActiPatch, Allay & RecoveryRx www.sultanahholding.com
Serbia Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Singapore Astonix ActiPatch, Allay & RecoveryRx www.astonixlife.com
Slovenia Zephyrus d.o.o. ActiPatch, Allay & RecoveryRx www.akomed.com
Spain Palex Medical SA ActiPatch, Allay & RecoveryRx www.palexmedical.com/en/
Venezuela Comercializadora Almed ActiPatch & RecoveryRx

-



~BioElectronics Corporation Website~
http://bielcorp.com/

State of Incorporation: MD
Year of Incorporation 2000

~BioElectronics Corporate Headquarters~
4539 Metropolitan Ct.
Frederick, MD 21704
Toll Free: 866-757-2284
Phone: 301-874-4890
Fax: 301-644-3937

Office Hours:
9 A.M. - 5 P.M. EST

E- mail:info@actipatch.net


$$$$$==Updates for 2014 / Products / FDA ==$$$$$ 


2014 Oxford Pharmascience Group (OXP) is sponsoring BIELhttp://www.oxfordpharmascience.com/content/investors/share_price.asp 

Park Lane Hotel, Piccadilly, London 
Thursday, 6th March 2014
 

http://www.otc-bulletin.com/awards/pdfs/Nominations-Supplement-2014.pdf 
 


Additional Products Improvements 2014 http://chiropractorofthefuture.com/ 
 
 

$$$$$==BIEL DD POSTED 02/13/14==$$$$$ 

 From Oct 2013 ::: The innovation award we won from OTC Bulletin in March has yielded more than a good-looking plaque. Our products caught the attention of several interested parties including three of Europe’s largest pharmaceutical companies. We are actively exploring distribution and co-branding licensing proposals with all three. In each case these proposals offer significant potential advantages to the company. The most immediate would be product sales to companies with well-established, funded marketing and sales channels, and licensing agreements with royalty income. This strategy maintains our first-to-market advantage while giving us access to a good income stream and marketing power and access to capital (without further dilution). Another advantage would be the spill-over affect associated with this co-branding alliance on our other brands and obtaining additional distribution in other regions. http://www.bielcorp.com/investors/letter-from-the-president/ 

 
2014 Oxford Pharmascience Group (OXP) is sponsoring BIELhttp://www.oxfordpharmascience.com/content/investors/share_price.asp 

Park Lane Hotel, Piccadilly, London 
Thursday, 6th March 2014 

http://www.otc-bulletin.com/awards/pdfs/Nominations-Supplement-2014.pdf 

 

 

Now in over 20 US Location for sale Additional Products Improvements 2014http://chiropractorofthefuture.com/ 
 

 

LOOKS LIKE AN UPDATE ON 2014 FDA 

Updated by FDA :::: 
2014 


http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?start_search=1&OwnerOperatorNumber=10028114

Now listed as Active 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?rid=98022 

 
Patents:::: https://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Bioelectronics+Corp.%22

 

 
 

 



Approved for Olympics:                                                                                LOOK AT DR Oz
 

 didn't notice that the FDA had uploaded additional info from the meeting, including a summary. IMO, things are pointing towards Class II w/ a lot of special controls. Probably looking at months away from a final order (see page 20 of Reclassification Process). 


FDA Presentation 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/UCM354307.pdf 

Brief Summary of the Meeting 
Note: Debate over potential unreasonable risk of injury or illness which is key to Class II or III designation 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/UCM354284.pdf 

Reclassification Process Flow Chart 
Note: Page 18 w/ respect to panel & FDA stating there is sufficient data to establish special controls. 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/UCM354300.pdf 

Nonthermal SWD Regulatory Background 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/UCM354304.pdf 

Intro & Reg Reference Sheet 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/UCM352572.pdf 



 

Welcome to Boots

The UK's leading pharmacy-led health and beauty retailer

Boots UK is a member of Alliance Boots, an international pharmacy-led health and beauty group.

Our purpose is to help our customers look and feel better than they ever thought possible.  We have close to 2,500 stores from local community pharmacies to large destination health and beauty stores.  We offer fantastic products and services and you'll be cared for by expert, friendly people.   http://www.boots-uk.com/   
 

Walgreen to Spend $6.7 Billion on Alliance Boots Stake - WSJ.com  

 

 
 
 

BioElectronics Investor Updates

 

Tuesday, February 11, 2014

ActiPatch® and Smart Insole™ Pain Relief Products Nominated for Marketing Awards by the OTC Bulletin
ActiPatch® and Smart Insole™ Pain Relief Products Nominated for Marketing Awards by the OTC Bulletin

 

Recent Updates


GlaxoSmithKline wires up $50M VC fund for bioelectronic treatment effort

Read more: 
GlaxoSmithKline wires up $50M VC fund for bioelectronic treatment effort - FierceBiotech http://www.fiercebiotech.com/story/glaxosmithkline-wires-50m-vc-fund-bioelectronic-treatment-effort/2013-08-08#ixzz2tN79rRsT 
Subscribe at FierceBiotech


01/31/2014 ---  http://www.cricketworld.com/win-actipatch-for-pain-free-living/36496.htm

 

ActiPatch, a musculoskeletal pain reliever

December 12, 2013 @ 10:14 am · Filed under Pain Management

Dr. Christine Dumas, public affairs spokesperson and patient advocate for BioElectronics Corporation, the maker of ActiPatch, which reduces musculoskeletal pain in different areas of the body joins eHealth Radio and the Pain Management Channel.    http://ehealthradio.podbean.com/?s=dumas 

 






Disclaimer:

This Un-Official BIEL Message Board was created by shareholders of BIEL for Shareholders of BIEL. The intent of this board is to help shareholders and also bring discussions about BIEL to a central place.
Information above is gathered from either the internet or from other sources that could prove to be unreliable. Please do your own Due Diligence as some information may be out of date. IHub and the Moderators of this board (BIEL) will not claim nor hold any responsibility for a person(s) financial decisions. If any in-valid information is located on the BIEL board, please notify one of the moderators immediately so corrections can be made.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BIEL
Current Price
Volume:
Bid Ask Day's Range
Wiki
SureTrader
PostSubject
#76485  Sticky Note Brilliant post Steve - thank you. . . Simpsonly 05/03/16 10:07:57 AM
#75509  Sticky Note BIEL Accomplishments 4/2016 srinsocal 04/20/16 12:28:17 AM
#71363  Sticky Note ****SEC litigation against BIEL - Link***** MUST_ SEE_BEFORE_BUYING_SCAM!!!! stockdarockk 02/07/16 10:37:09 PM
#66436  Sticky Note AS 15B per Dec 4 Articles of Amendment Det_Robert_Thorne 12/15/15 12:09:29 PM
#65459  Sticky Note Approval on the way- what changed since 2010 denial- dcsteve 12/06/15 08:12:58 PM
#58192  Sticky Note BOARD WARNING - Please Read: IH Admin [Shelly] 10/15/15 02:50:34 PM
#76539   Key and pertinent words "unproven allegations" Allegations are Steve43 05/03/16 02:18:31 PM
#76538   Does anyone know that there is other Numbers Run2wahoo 05/03/16 02:13:01 PM
#76537   As with the story on Braun's $100 million srinsocal 05/03/16 01:43:08 PM
#76536   Flip all you want! Go for it. As art2426 05/03/16 01:36:24 PM
#76535   Just a difference in perspective between a steak bieliever 05/03/16 01:35:16 PM
#76534   ...after showing the Daily Mail and Daily Express llh222 05/03/16 01:24:01 PM
#76533   Even if that is the case, it is DewmBoom 05/03/16 01:00:43 PM
#76532   i MEAN something from CEO saying rejected/pending clinical trials REDZONE 05/03/16 12:42:46 PM
#76531   did anyone get any info on a FDA UPDATE REDZONE 05/03/16 12:42:09 PM
#76530   massive potential here aside from the issues REDZONE 05/03/16 12:41:26 PM
#76529   sorry, sometime negative post gets a few hits REDZONE 05/03/16 12:41:03 PM
#76528   Halting is not in the public interest. Essentially, DewmBoom 05/03/16 12:22:55 PM
#76527   Chloe!!!!! You're back!!!! You've been sorely missed!!!!! Simpsonly 05/03/16 12:16:58 PM
#76526   No I don't think we ignore the issues chloe31200 05/03/16 12:16:29 PM
#76525   Hey REDZONE Simpsonly 05/03/16 12:12:09 PM
#76524   Yes you said it before bieliever 05/03/16 12:11:13 PM
#76523   And perhaps Q1 results a few days early? bieliever 05/03/16 12:08:36 PM
#76522   Dude U stated on the post u will sell Erbb 05/03/16 12:07:54 PM
#76521   ??????????? Sold all the shares.... Erbb 05/03/16 12:06:27 PM
#76520   I have been following the sales of Actipatch yankee55 05/03/16 12:06:00 PM
#76519   Old news Erbb 05/03/16 12:04:04 PM
#76518   if we are holders we should know "problems" REDZONE 05/03/16 11:59:03 AM
#76517   no FDA in months issues CEO doesn't=want-make-public REDZONE 05/03/16 11:58:41 AM
#76516   A sticky it is! yankee55 05/03/16 11:58:19 AM
#76515   and i've said before flip/while we can... REDZONE 05/03/16 11:57:35 AM
#76514   i talk about the good/bad BIEL REDZONE 05/03/16 11:57:14 AM
#76513   so think we should ignore the SEC issues? REDZONE 05/03/16 11:56:43 AM
#76512   Yawn......... Gramps 05/03/16 11:56:40 AM
#76511   Although I don't have the power to do Gramps 05/03/16 11:55:39 AM
#76510   Just another attempt to initiate and spread some chloe31200 05/03/16 11:54:12 AM
#76509   Your transparency annoys me. stallion70 05/03/16 11:44:54 AM
#76508   where do you SEE SEC allegations like this REDZONE 05/03/16 11:42:06 AM
#76507   Biel has the same probability of halting as DewmBoom 05/03/16 11:38:23 AM
#76506   Chicken Little will find out in time that lizanne1890 05/03/16 11:36:45 AM
#76505   Just saying if this halts tomorrow , all REDZONE 05/03/16 11:33:05 AM
#76504   Wow! Play with extreme caution on a sub DewmBoom 05/03/16 11:31:17 AM
#76503   "motion is DENIED AS MOOT" then "request is RVC 05/03/16 11:30:55 AM
#76502   i say play with extreme caution REDZONE 05/03/16 11:19:44 AM
#76501   was reading 04/2016 SEC UPDATE https://www.sec.gov/alj/aljorders/2016/ap-3761.pd REDZONE 05/03/16 11:16:54 AM
#76500   Too much sugar in the diet makes one Steve43 05/03/16 11:00:09 AM
#76499   Can't wait for the day when some of Simpsonly 05/03/16 10:56:02 AM
#76498   The sky is falling ! The sky is strikeitrich 05/03/16 10:55:18 AM
#76497   No "I" think it's the more you "think" Steve43 05/03/16 10:55:04 AM
#76495   You won't get proof like I won't get Steve43 05/03/16 10:49:50 AM
#76493   continues to leverage TOXIC Dilution campaign to milk whitepanda 05/03/16 10:41:52 AM
#76492   You guess my companies were "two failed companies" Steve43 05/03/16 10:41:50 AM
#76491   Yes it's being played out right now in Steve43 05/03/16 10:34:28 AM
#76489   Speaking of playing games with a stock . Simpsonly 05/03/16 10:27:45 AM
#76488   I owned two legitimate companies that I continuously Steve43 05/03/16 10:26:12 AM
#76487   You're welcome and by all means add what Steve43 05/03/16 10:17:53 AM
PostSubject